Overview

A Study to Investigate Efficacy and Safety of Apremilast 30 mg Twice Daily (BID) in Chinese Participants With Moderate to Severe Plaque-type Psoriasis (PsO)

Status:
Recruiting

Trial end date:
2025-12-24

Target enrollment:

Participant gender:

Summary

The study aims to evaluate the clinical efficacy of oral apremilast 30 mg BID compared with placebo in Chinese participants with moderate to severe PsO

Phase:

Phase 3

Details

Lead Sponsor:

Amgen

Treatments:

Apremilast